Physician profile
Glenn L Zellman
NPI 1285611582
$1,001,716.02
in general payments reported to CMS, 2019-2025
40 companies · $253K in 2025
The $253K reported for 2025 was more than what 99% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150K · 2020: $57K · 2021: $39K · 2022: $126K · 2023: $196K · 2024: $181K · 2025: $253K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $501K · Consulting Fee: $52K · Travel and Lodging: $38K · Food and Beverage: $34K · Honoraria: $5,660 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500,600.49 |
| Consulting Fee | $51,540.65 |
| Travel and Lodging | $38,002.84 |
| Food and Beverage | $33,690.70 |
| Honoraria | $5,660.08 |
| Education | $132.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $191,006.64 | 2019-2022 | |
| Janssen Biotech, INC. | $179,321.49 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $144,441.46 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Ucb, INC. | $111,877.11 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $99,483.08 | 2019-2025 | |
| Galderma Laboratories, L.P. | $60,369.33 | 2019-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $50,730.13 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $34,274.88 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $31,848.38 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $23,204.43 | 2023-2024 | Vtama |
| Leo Pharma INC. | $20,792.45 | 2019-2025 | Anzupgo, Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13,447.60 | 2019-2024 | Siliq, Targretin, Duobrii |
| Botanix Sb INC | $9,828.77 | 2025 | Sofdra |
| Organon LLC | $7,121.01 | 2024-2025 | Vtama, Hadlima |
| Abbvie INC. | $5,615.28 | 2019-2025 | Skyrizi, Rinvoq |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $5,072.39 | 2019-2025 | Odomzo, Blu-U, Ilumya |
| Amgen INC. | $4,177.55 | 2019-2025 | Otezla, Otezla, Enbrel |
| Incyte Corporation | $3,451.07 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $1,371.12 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $1,304.44 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $744.09 | 2019-2025 | |
| Celgene Corporation | $563.10 | 2019 | |
| Genentech USA, INC. | $549.24 | 2019-2023 | Erivedge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.08 | 2022-2023 | Spevigo |
| Kyowa Kirin, INC. | $183.23 | 2020-2025 | Poteligeo |
| Biofrontera INC. | $176.66 | 2020-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $101.69 | 2019-2023 | Seysara, Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $80.10 | 2021-2025 | Valchlor |
| Osiris Therapeutics INC. | $61.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $40.44 | 2019 | |
| Smith+Nephew, INC. | $37.42 | 2019-2021 | |
| Organogenesis INC. | $35.52 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $29.34 | 2019 | |
| Blueprint Medicines Corporation | $23.68 | 2023 | |
| Solta Medical, A Division of Bausch Health US, LLC | $23.44 | 2025 | |
| Mayne Pharma Commercial LLC | $17.89 | 2020 | |
| Celltrion USA INC. | $14.45 | 2024 | Vegzelma |
| Nabriva Therapeutics, Plc | $12.29 | 2021 | |
| Merck Sharp & Dohme LLC | $12.22 | 2019 | |
| Epi Health, LLC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Zellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.